Venture capital allocation within the biotechnology sector contracted overall by 12%, but early-stage funding for targeted drug delivery systems increased by 31%. Investors are focusing on technologies that precisely target specific organ tissue.
Overcoming Tissue Specificity Barriers
First-generation lipid nanoparticles concentrated primarily in the liver, limiting therapeutic reach. Second-generation formulations currently in Phase II trials demonstrate successful extrahepatic delivery, opening avenues for localized genetic therapies.